Health economic evaluation of type 2 diabetes mellitus: A clinical practice focused review

Clinical Medicine Insights: Endocrinology and Diabetes

Volumn 8, Issue , 2015, Pages 13-19

  Liebl, Andreas ^a   Khunti, Kamlesh ^b   Orozco Beltran, Domingo ^c   Yale, Jean Francois ^d  

^a Fachklinik Bad Heilbrunn   (Germany)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^d ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Cost effectiveness; Healthcare economics (operational domain); Hyperglycemia; Hypoglycemia; Insulin; Oral antidiabetic agents; Type 2 diabetes (clinical domain)

Indexed keywords

BIPHASIC INSULIN; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ADVERSE OUTCOME; CLINICAL PRACTICE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOSPITAL CARE; HOSPITAL PATIENT; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LIFE EXPECTANCY; MEDICAL EDUCATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION EDUCATION; OUTCOME ASSESSMENT; PATIENT CARE; PEER REVIEW; PRESCRIPTION; PRIMARY MEDICAL CARE; QUALITY OF LIFE; REVIEW; SELF CARE; SELF MONITORING; WEIGHT GAIN;

EID: 84925868067     PISSN: None     EISSN: 11795514     Source Type: Journal    
DOI: 10.4137/CMED.S20906     Document Type: Review

References (76)

1. Farag YM, Gaballa MR. Diabesity: an overview of a rising epidemic. Nephrol Dial Transplant. 2011;26(1):28-35.
2. World Health Organization. Diabetes Factsheet. Geneva: World Health Organization; 2013.
3. Gillies CL, Lambert PC, Abrams KR, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ. 2008; 336(7654):1180-1185.
4. Currie CJ, Gale EA, Poole CD. Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007. Diabet Med. 2010;27(8):938-948.
5. Massi-Benedetti M. The cost of diabetes Type II in Europe: the CODE-2 Study. Diabetologia. 2002;45(7):S1-S4.
6. Liebl A, Neiss A, Spannheimer A, et al. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany—results from the CODE-2 study. Exp Clin Endocrinol Diabetes. 2002;110(1):10-16.
7. Bottomley JM; T2ARDIS Steering Committee. Managing care of type 2 diabetes. Learnings from T2ARDIS. Br J Diabetes Vasc Dis. 2001;1:68-72.
8. Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia. 2002;45(7):S13-S17.
9. Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14(36):1-248.
10. Alvarez GF, Mavros P, Nocea G, Alemao E, Alexander CM, Yin D. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the real-life effectiveness and care patterns of diabetes management (RECAP-DM) study. Diabetes Obes Metab. 2008;10:8-15.
11. Ramsdell JW, Braunstein SN, Stephens JM, Bell CF, Botteman MF, Devine ST. Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus. Pharmacoeconomics. 2003; 21(11):819-837.
12. Grunberger G. The importance of early insulin adoption in type 2 diabetes management. Internet J Fam Pract. 2008;7(2). Available at: https://ispub.com?IJFP/7/2/5172.
13. Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia. 2002; 45(7):S5-S12.
14. Williams R, Baxter H, Bottomley J, et al. CODE-2* UK: our contribution to a European study of the costs of type 2 diabetes. Practical Diabetes Int. 2001; 18:235-238.
15. Gray A, Fenn P, McGuire A. The cost of insulin-dependent diabetes mellitus (IDDM) in England and Wales. Diabet Med. 1995;12(12):1068-1076.
16. Moore P. Type 2 diabetes is a major drain on resources. BMJ. 2000;320(7237):732.
17. This is Money website. Historic inflation calculator. 2011. Available at: http:/?www.thisismoney.co.uk/historic-inflation-calculator.
18. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855-862.
19. Liebl A, Spannheimer A, Reitberger U, Gortz A. [Costs of long-term complications in type 2 diabetes patients in Germany. Results of the CODE-2 Study]. Med Klin (Munich). 2002;97(12):713-719.
20. Mata M, Antonanzas F, Tafalla M, Sanz P. [The cost of type 2 diabetes in Spain: the CODE-2 study]. Gac Sanit. 2002;16(6):511-520.
21. Xie X, Vondeling H. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China. Value Health. 2008;11(suppl 1):S23-S32.
22. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia. 2005;48(5):868-877.
23. Gray A, Clarke P, Farmer A, Holman R. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). BMJ. 2002;325(7369):860.
24. Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ. 2000;320(7246):1373-1378.
25. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26(9):733-744.
26. Boren SA, Fitzner KA, Panhalkar PS, Specker JE. Costs and benefits associated with diabetes education. Diabetes Educator. 2009;35(1):72-96.
27. Gillett M, Dallosso HM, Dixon S, et al. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. BMJ. 2010;341:c4093.
28. Duke SA, Colagiuri S, Colagiuri R. Individual patient education for people with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2009;1:CD005268.
29. Loveman E, Cave C, Green C, Royle P, Dunn N, Waugh N. The clinical and cost-effectiveness of patient education models for diabetes: a systematic review and economic evaluation. Health Technol Assess. 2003;7(22):iii1-iii190.
30. Davies MJ, Heller S, Skinner TC, et al; Diabetes Education and Self Management for Ongoing and Newly Diagnosed Collaborative. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ. 2008;336(7642):491-495.
31. Khunti K, Gray LJ, Skinner T, et al. Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care. BMJ. 2012;344:e2333.
32. Montori VM, Fernandez-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med. 2009;150(11):803-808.
33. Boutati EI, Raptis SA. Self-monitoring of blood glucose as part of the integral care of type 2 diabetes. Diabetes Care. 2009;32(suppl 2):S205-S210.
34. Clar C, Barnard K, Cummins E, Royle P, Waugh N. Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technol Assess. 2010;14(12): 1-140.
35. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Clin Diabetes. 2009;27(1):4-16.
36. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract. 2007;57(539):455-460.
37. Heine RJ, Diamant M, Mbanya JC, Nathan DM. Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? BMJ. 2006;333(7580): 1200-1204.
38. Philippe J, Raccah D. Treating type 2 diabetes: how safe are current therapeutic agents? Int J Clin Pract. 2009;63(2):321-332.
39. Burke GL, Bertoni AG, Shea S, et al. The impact of obesity on cardiovascular disease risk factors and subclinical vascular disease: the Multi-Ethnic Study of Atherosclerosis. Arch Intern Med. 2008;168(9):928-935.
40. Look AHEAD Research Group; Pi-Sunyer X, Blackburn G, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6): 1374-1383.
41. Prospective Studies Collaboration; Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083-1096.
42. Nauck M, Frid A, Hermansen K, LEAD-2 Study Group, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84-90.
43. Valentine WJ, Palmer AJ, Lammert M, Langer J, Brandle M. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clin Ther. 2011; 33(11):1698-1712.
44. Valentine WJ, Goodall G, Aagren M, Nielsen S, Palmer AJ, Erny-Albrecht K. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. Adv Ther. 2008;25(6):567-584.
45. Brandle M, Azoulay M, Greiner RA. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the diabetes mellitus model in patients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther. 2007;45(4):203-220.
46. Rosenblum MS, Kane MP. Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with type 2 diabetes mellitus. J Manag Care Pharm. 2003;9(4):309-316.
47. Goodall G, Sarpong EM, Hayes C, Valentine WJ. The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocr Disord. 2009;9:19.
48. Liebl A, Breitscheidel L, Nicolay C, Happich M. Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study. Curr Med Res Opin. 2008; 24(8):2349-2358.
49. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411-3417.
50. Norton E. The business of intensive insulin therapy for type 2 diabetes patients: where it all began for me. J Diabetes Sci Technol. 2009;3(6):1521-1523.
51. Shaefer J. Patient and physician barriers to instituting insulin therapy: a case-based overview. Insulin. 2007;2(suppl 2):S41-S46.
52. Hisashige A, Katayama T, Mikasa H. Costs and effectiveness of insulin therapy for type 2 diabetes. Value Health. 2001;4(2):113.
53. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am. 2001;30(4):935-982.
54. Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther. 2010;12(S1):S101-S108.
55. Peyrot M, Rubin RR, Lauritzen T, et al; International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673-2679.
56. Leichter S. Is the use of insulin analogues cost-effective? Adv Ther. 2008;25(4): 285-299.
57. Lee LJ, Yu AP, Johnson SJ, et al. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis. Diabetes Res Clin Pract. 2010;87(1):108-116.
58. National Institute for Health and Clinical Excellence (NICE). Type 2 Diabetes: Newer Agents for Blood Glucose Control in Type 2 Diabetes. NICE Website Guidance Pages. London: NICE; 2009.
59. Jonsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with type 2 diabetes in Sweden. Value Health. 2006;9(3):193-198.
60. Lundkvist J, Berne C, Bolinder B, Jonsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ. 2005;6(3):197-202.
61. Holstein A, Plaschke A, Egberts EH. Incidence and costs of severe hypoglycemia. Diabetes Care. 2002;25(11):2109-2110.
62. Yu AP, Wu EQ, Birnbaum HG, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin. 2007;23(9):2157-2169.
63. Dennett SL, Boye KS, Yurgin NR. The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. Value Health. 2008;11(3):478-486.
64. Khunti K, Davies M. Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances. Diabetes Obes Metab. 2010;12(6):474-484.
65. Cavan DA, Ziegler R, Cranston I, et al. Automated bolus advisor control and usability study (ABACUS): does use of an insulin bolus advisor improve glycaemic control in patients failing multiple daily insulin injection (MDI) therapy? [NCT01460446]. BMC Fam Pract. 2012;13:102.
66. Reach G, Zerrouki A, Leclercq D, d’Ivernois JF. Adjusting insulin doses: from knowledge to decision. Patient Educ Couns. 2005;56(1):98-103.
67. Hammer M, Lammert M, Mejias SM, Kern W, Frier BM. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12(4):281-290.
68. Leese GP, Wang J, Broomhall J, et al; DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26(4):1176-1180.
69. Brod M, Busk AK, Kragh N, Christensen TE. Underestimated impact of non-severe nocturnal hypoglycemic events (NHEs) on patients’ functioning and well being: approximately 30% of events result in work absenteeism and productivity loss. Diabetes. 2011;60(suppl 1):A329.
70. McEwan P, Evans M, Kan H, Bergenheim K. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. Diabetes Obes Metab. 2010;12(5):431-436.
71. Dailey G, Strange P. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes. Am J Manag Care. 2008;14(1):25-30.
72. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080-3086.
73. Blonde L, Merilainen M, Karwe V, Raskin P. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets—the TITRATE study. Diabetes Obes Metab. 2009;11(6):623-631.
74. Zinman B, Philis-Tsimikas A, Cariou B, et al; NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464-2471.
75. Bergenstal RM, Rosenstock J, Arakaki RF. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care. 2012; 35(11):2140-2147.
76. Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34(3): 669-674.